Standard Hormone Panels: What They Diagnose vs. What They Don't Screen For

What is actually well established

TSH and free T4 immunoassays, total and free testosterone assays, and cortisol measurement (including ACTH stimulation testing) are mature laboratory methods with decades of analytical validation and clearly defined reference ranges. None of that is in question.

What is also well established is their role once there is a clinical reason to look: a patient with fatigue, weight change, cold intolerance, or a goiter is a reasonable candidate for thyroid testing. A man with low libido, erectile dysfunction, and reduced energy is a reasonable candidate for testosterone testing, but the Endocrine Society is explicit that diagnosis requires consistent symptoms plus repeated, unequivocally low levels, not a single value in isolation. A patient with unexplained hypotension, hyperpigmentation, or an acute illness that does not track normally is a reasonable candidate for cortisol and ACTH testing, and the Endocrine Society's adrenal insufficiency guideline builds its whole diagnostic pathway around testing people who already have signs or predisposing risk, not the general population.[2][3]

What the evidence shows for this specific use

The question this review is built around is narrower than "do these tests work." It is: does the evidence support running the same panels on adults who have no symptoms, as a screening exercise rather than a response to a clinical question? Here the picture changes.

The U.S. Preventive Services Task Force reviewed the evidence for thyroid screening in asymptomatic adults and concluded that current evidence is insufficient to assess the balance of benefits and harms. That is a specific, limited finding: it is not proof that screening causes harm, and it is not proof that it helps. It means the trials needed to show a net benefit from finding and treating thyroid dysfunction in people who feel fine simply have not been done to a standard that supports a recommendation either way.[1]

For testosterone, the evidence position is more direct. The Endocrine Society's clinical practice guideline recommends against population-based screening for testosterone deficiency. Its diagnostic pathway is built on symptoms first, with laboratory confirmation second, precisely because testosterone levels vary by time of day, illness, and assay, and a low number without a matching clinical picture is not a diagnosis of hypogonadism.[2]

For cortisol and ACTH, the same guideline logic applies even though the source describing it is a diagnostic guideline rather than a screening statement: dynamic testing such as ACTH stimulation is recommended for people with a clinical reason to suspect adrenal insufficiency, and the guideline frames interpretation around pretest probability from symptoms and predisposing conditions. There is no equivalent recommendation, or supporting evidence, for using cortisol or ACTH testing as a general screen in adults without a clinical indication.[3]

The trap: an abnormal number is not a diagnosis

Every one of these guidelines converges on the same structural point: a test result only becomes diagnostically meaningful when it is interpreted against a specific clinical question and, usually, confirmed on repeat testing. Run the same panel on someone with no symptoms and no pretest probability, and a single value outside the reference range is far more likely to be noise, assay variability, or a transient physiological state than true disease.[2]

What a direct test of this question found

The clearest test of whether "fixing the number" helps came from the TRUST trial, a randomized, placebo-controlled study of levothyroxine in 737 adults aged 65 and older with subclinical hypothyroidism, meaning a mildly elevated TSH with a normal free T4, the exact pattern an opportunistic or screening panel is likely to turn up in an asymptomatic or vaguely symptomatic older adult. Levothyroxine treatment produced no improvement in thyroid-related symptoms or quality of life compared with placebo.[4]

This is a genuine null result, not an absence of study, and it belongs in this review rather than being left out. It does not settle every question about subclinical thyroid disease in every population, and it says nothing directly about testosterone or cortisol. But it is the strongest available evidence that detecting and correcting a mildly abnormal hormone value in someone who was not clearly symptomatic to begin with does not reliably translate into feeling better, which is the core assumption behind using these panels as a screening tool.[4]

Beyond that trial, the honest state of the evidence is one of absence rather than reassurance. The USPSTF's own conclusion was "insufficient evidence," not "no benefit," and no equivalent large randomized trial exists for opportunistic testosterone or cortisol screening in asymptomatic adults. That gap should not be read as quiet permission to screen; it means the case for it has not been made either way.[1]

What this means for you

Thyroid, sex-hormone, and cortisol/ACTH testing is ordered as part of a physician-led diagnostic workup when there is a clinical reason to look: symptoms, history, examination findings, or a specific question the physician is trying to answer. These panels are not run as a fixed battery applied to every client regardless of presentation, because the evidence above does not support that as a screening strategy.[1][2]

When a result comes back outside the reference range, the physician's job is to weigh it against the person in front of them, not to treat the number on its own. That means checking whether the result matches the symptoms that prompted testing, repeating the test where guidelines call for confirmation before any treatment decision, and being willing to tell a patient that an isolated mildly abnormal value, in the absence of a matching clinical picture, is not evidence of disease and is not, on its own, a reason to start treatment.[3]

AION does not market these panels as a stand-alone wellness or preventive hormone screen for people without symptoms, because that use is not what the underlying evidence supports.